The present announcement does not concern the award of a public contract within the meaning of the procurement coordination guideline (2014/24 / EU) or the antitrust law. In the interest of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The process designation "open procedure" (Section IV.1.1) used in the context of the present announcement text is owed to the specifications of the announcement form. This, as well as the use of the "TED" medium, does not involve any submission to regulations under procurement law, the validity of which is not prescribed by law or procurement ordinances. It is a framework agreement with the option to join, which relates to various active ingredients.

The subject of the contract are drugs that contain the active ingredient adalimumab.